Summary
CereportTM (RMP-7) is a selective bradykinin B2 receptor agonist which increases the permeability of the ‘blood–brain tumour barrier’ (BBTB) to increase delivery of chemotherapeutic agents to brain tumours. A series of experiments was performed in an RG2 rodent model of glioma to evaluate and refine intravenous (i.v.) parameters to optimize Cereport’s clinical utility. The first experiment demonstrated that while carboplatin levels were increased by twofold when given as a bolus during the Cereport infusion, no increase in carboplatin levels were seen when Cereport and carboplatin were simultaneously co-infused for 15 min. A subsequent experiment established that a major factor responsible for the lack of an effect with the co-infusion paradigm was tachyphylaxis to Cereport during the 15 min infusion, for a progressively diminished response to Cereport occurred over that time frame, as plasma levels of carboplatin were rising. A final experiment adjusted the timing of the Cereport and carboplatin infusions so that higher plasma carboplatin levels were achieved prior to initiating the Cereport infusion. Significant uptake effects were achieved when the carboplatin infusion preceded the Cereport infusion by 10 min (i.e. 5 min overlap in the delivery of the two agents). Collectively, these data provide the first systematic evaluation of dosing parameters involving receptor-mediated changes in BBTB permeability and provide new information regarding the pharmacodynamics and potential clinical use of Cereport.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bartus, R. T., Elliott, P. J., Dean, R. L., Hayward, N. J., Nagle, R. L., Huff, M. R., Snodgrass, P. A. & Blunt, D. G. (1996a). Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 142: 14–28.
Bartus, R. T., Elliott, P. J., Hayward, N. J., Dean, R. L., McEwen, E. & Fisher, S. K. (1996b). Permeability of the blood brain barrier by the bradykinin agonist, RMP-7: evidence for a sensitive, auto-regulated, receptor-mediated system. Immunopharmacology 33: 270–278.
Bartus, R. T., Snodgrass, P., Dean, R., Kim, B., Black, K. & Emerich, D. (1999). Use of Cereport (RMP-7) to increase delivery of carboplatin to gliomas: insight and parameters for intracarotid infusion via a single-lumen cannula. Drug Delivery 6: 15–21.
Black, K. L. (1995). Biochemical opening of the blood–brain barrier. Adv Drug Rev 15: 37–52.
Black, K. L., Cloughesy, T., Huang, S., Gobin, Y., Zhou, Y., Grous, J., Nelson, G., Farahani, K., Hoh, K. & Phelps, M. (1997). Intracarotid infusion of RMP-7, a bradykinin analog, and transport of gallium-68 ethylenediamine tetraacetic acid into human gliomas. J Neurosurg 86: 603–609.
Burch, R., Kyle, D. & Stormann, T. (1993). Molecular Biology and Pharmacology of Bradykinin Receptors. RG Landes: Austin
Chow, K. L., Cloughesy, T. F., Sayre, J. W., Gobin, Y. P., Villablance, J. P. & Vinuela, F. (1998). Factors predictive of response to selective intra-arterial chemotherapy, Conference Proceeding American Soc Clin Oncol/Am Soc Neuro-Oncol: Los Angeles
Doctrow, S. R., Abelleira, S. M., Curry, L. A., Heller-Harrison, R., Kozarich, J. W., Malfroy, B., McCarroll, L. A., Morgan, K. G., Morrow, A. R., Musso, G. F., Smart, J. L., Straub, J. A. & Turnball, B. (1994). The bradykinin analog RMP-7 increases extracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther 271: 229–237.
Elliott, P. J., Hayward, N. J., Dean, R. L., Blunt, D. G. & Bartus, R. T. (1996a). Intravenous RMP-7 selectively increases uptake of carboplatin into rat brain tumors. Cancer Res 56: 3998–4005.
Elliott, P. J., Hayward, N. J., Huff, M. R., Nagle, T. L., Black, K. L. & Bartus, R. T. (1996b). Unlocking the blood–brain barrier: a role for RMP-7 in brain tumor therapy. Exp Neurol 141: 214–224.
Elliott, P. J., Hayward, N. J., Dean, R. L. & Bartus, R. T. (1996c). Dissociation of blood–brain barrier permeability and the hypotensive effects of the bradykinin B2 agonist RMP-7. Immunopharmacology 33: 205–208.
Ford, J. M., Miles, K. A., Hayball, M. P., Bearcroft, P. W., Bleehen, N. M. & Osborn, C. S. (1996). A simplified technique for measurement of blood–brain barrier permeability using CT: preliminary results of the effect of RMP-7. In Quantitative Imaging in Oncology, Proceedings of the 19th LH Grey Conference Faulkner K British Institute of Radiology: 126–155.
Gregor, A., Lind, M. & Osborn, C. (1997). Intravenous RMP-7 and carboplatin: efficacy of a new treatment for recurrent malignant glioma, Conference Proceeding: Am Soc Clin Oncol/Am Soc Neuro-Oncol: Charlottesville, VA
Grous, J., Elliott, P. & Bartus, R. T. (1996). Development of RMP-7: a novel bradykinin agonist that increases delivery of chemotherapeutics to gliomas. In Adjuvant Therapy of Cancer
Inamura, T. & Black, K. L. (1994). Bradykinin selectively opens blood–tumor barrier in experimental brain tumors. J Cereb Blood Flow Metab 14: 862–870.
Inamura, T., Nomura, T., Bartus, R. T. & Black, K. L. (1994). Intracarotid infusion of RMP-7, a bradykinin analog: a method for selective drug delivery to brain tumors. J Neurosurg 81: 752–758.
Matsukado, K., Inamura, T., Nakano, S., Fukui, M., Bartus, R. T. & Black, K. L. (1996). Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39: 125–134.
Matsukado, K., Sugita, M. & Black, K. L. (1998). Intracartoid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas. Brain Res 792: 10–15.
Munoz, C. M. & Lee-Lundberg, L. M. F. (1992). Receptor-mediated internalization of bradykinin. JBC 267: 303–309.
Neuwelt, E. A. & Rapoport, S. I. (1984). Modification of the blood–brain barrier in the chemotherapy of malignant brain tumors. Fed Proc 43: 214–219.
Neuwelt, E. A., Hill, S. A. & Frenkel, E. P. (1984). Osmotic blood–brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening. Neurosurgery 15: 362–366.
Neuwelt, E. A., Barnett, P. A., McCormick, C. I., Frenkel, E. P. & Minna, J. D. (1985). Osmotic blood–brain barrier modification: monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery 17: 419–423.
Nomura, T., Inamura, T. & Black, K. L. (1994). Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 659: 62–66.
Ohno, K., Pettigrew, K. & Rapoport, S. (1978). Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 253: H299–H307.
Pellegrino, L. J., Pellegrino, A. S. & Cushman, A. J. (1986). A Stereotaxic Atlas of the Rat Brain. Plenum Press: New York
Prados, M., Schold, H., Fine, H., Jaeckle, K., Hochberg, F. & Mechtler, L. et al (1997). Randomized placebo controlled phase II study of i.v. carboplatin with or without i.v. RMP-7 in patients with recurrent malignant glioma, Conference Proceeding: Am Soc Clin Oncol/Am Soc Neuro-Oncol: Charlottesville, VA
Radhakrishnan, K., Bohnen, N. I. & Kurland, L. T. (1994). Epidemilogy of brain tumours. In Brain Tumors: A Comprehensive Text, Morantz RA, Walsh JW (eds), pp. 23–32. Marcel Dekker: New York.
Riley, G., Kim, N., Watson, V., Gobin, Y., LeBel, C., Black, K. & Bartus, R. T. (1998). Intra-arterial administration of carboplatin and the BBB permeabilizing agent, RMP-7: a toxicological evaluation in swine. J Neuro-Oncol 36: 167–178.
Sanovich, E., Bartus, R. T., Friden, P. M., Dean, R. L., Le, H. Q. & Brightman, M. W. (1995). Pathway across blood–brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 705: 125–135.
Straub, J. A., Akiyama, A. & Parmar, P. (1994). In vitro plasma metabolism of RMP-7. Pharmaceut Res 11: 1673–1676.
Wahl, M., Unterberg, A., Whalley, E. T., Bacthmann, A., Young, A. R., Edvinsson, L. & Wagner, F. F. W. (1987). Effects of bradykinin on cerebral haemodynamics and blood–brain barrier function. In Peptidergic Mechanisms in the Cerebral Circulation, Edvinsson L Norwood: Chichester 166–190.
Warkne, P., Weyerbrock, A. & Ostertag, C. (1995). Effect of synthetic bradykinine RMP-7 on capillary permeability in glioblastoma multiforme, Cerebral Vascular Biology Conference: Paris
Ziylan, Y. Z., LeFauconnier, J. M., Bernard, G. & Bourre, J. M. (1988). Effect of dexamethasone on transport of alpha-aminoisobutyric acid and sucrose across the blood–brain barrier. J Neurochem 51: 1338–1342.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Emerich, D., Snodgrass, P., Dean, R. et al. Enhanced delivery of carboplatin into brain tumours with intravenous CereportTM (RMP-7): dramatic differences and insight gained from dosing parameters. Br J Cancer 80, 964–970 (1999). https://doi.org/10.1038/sj.bjc.6690450
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690450
Keywords
This article is cited by
-
The effect of regadenoson on the integrity of the human blood–brain barrier, a pilot study
Journal of Neuro-Oncology (2017)
-
Adenosine receptor signaling: a key to opening the blood–brain door
Fluids and Barriers of the CNS (2015)